We’ve recently updated our valuation analysis.

Vaxart Valuation

Is VXRT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VXRT?

Other financial metrics that can be useful for relative valuation.

VXRT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue309.1x
Enterprise Value/EBITDA-0.5x
PEG Ration/a

Price to Book Ratio vs Peers

How does VXRT's PB Ratio compare to its peers?

The above table shows the PB ratio for VXRT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.1x
CVM CEL-SCI
3.6x66.2%US$117.1m
TIL Instil Bio
0.3x0.7%US$115.5m
XFOR X4 Pharmaceuticals
2x32.6%US$126.4m
VSTM Verastem
2.4x50.8%US$148.2m
VXRT Vaxart
1.2x40.7%US$141.7m

Price-To-Book vs Peers: VXRT is good value based on its Price-To-Book Ratio (1.2x) compared to the peer average (2.1x).


Price to Earnings Ratio vs Industry

How does VXRT's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Book vs Industry: VXRT is good value based on its Price-To-Book Ratio (1.2x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is VXRT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VXRT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VXRT's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of VXRT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VXRT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VXRT's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VXRT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.08
US$6.63
+513.4%
47.5%US$10.00US$1.50n/a4
Jan ’24US$0.96
US$6.63
+589.5%
47.5%US$10.00US$1.50n/a4
Dec ’23US$1.17
US$7.75
+562.4%
19.1%US$10.00US$6.00n/a4
Nov ’23US$1.62
US$7.75
+378.4%
19.1%US$10.00US$6.00n/a4
Oct ’23US$2.18
US$7.75
+255.5%
19.1%US$10.00US$6.00n/a4
Sep ’23US$3.15
US$7.75
+146.0%
19.1%US$10.00US$6.00n/a4
Aug ’23US$3.58
US$11.40
+218.4%
34.0%US$18.00US$6.00n/a5
Jul ’23US$3.75
US$11.40
+204.0%
34.0%US$18.00US$6.00n/a5
Jun ’23US$3.45
US$11.40
+230.4%
34.0%US$18.00US$6.00n/a5
May ’23US$3.48
US$11.60
+233.3%
31.1%US$18.00US$7.00n/a5
Apr ’23US$5.20
US$11.60
+123.1%
31.1%US$18.00US$7.00n/a5
Mar ’23US$4.94
US$12.80
+159.1%
25.9%US$18.00US$9.00n/a5
Feb ’23US$5.17
US$12.80
+147.6%
25.9%US$18.00US$9.00US$1.095
Jan ’23US$6.27
US$12.80
+104.1%
25.9%US$18.00US$9.00US$0.965
Dec ’22US$7.04
US$13.00
+84.8%
25.3%US$18.00US$9.00US$1.175
Nov ’22US$6.97
US$12.50
+79.3%
28.0%US$18.00US$9.00US$1.624
Oct ’22US$7.18
US$12.50
+74.1%
28.0%US$18.00US$9.00US$2.184
Sep ’22US$8.99
US$12.50
+39.0%
28.0%US$18.00US$9.00US$3.154
Aug ’22US$7.19
US$12.50
+73.9%
28.0%US$18.00US$9.00US$3.584
Jul ’22US$7.68
US$12.50
+62.8%
28.0%US$18.00US$9.00US$3.754
Jun ’22US$6.59
US$11.50
+74.5%
13.0%US$13.00US$10.00US$3.452
May ’22US$10.78
US$13.33
+23.7%
21.5%US$17.00US$10.00US$3.483
Apr ’22US$6.10
US$13.33
+118.6%
21.5%US$17.00US$10.00US$5.203
Mar ’22US$7.55
US$17.67
+134.0%
9.6%US$20.00US$16.00US$4.943
Feb ’22US$15.57
US$17.67
+13.5%
9.6%US$20.00US$16.00US$5.173

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies